11/24
07:19 am
lyel
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
11/13
12:38 pm
lyel
Lyell Immunopharma reports Q3 results [Seeking Alpha]
Low
Report
Lyell Immunopharma reports Q3 results [Seeking Alpha]
11/12
04:32 pm
lyel
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]
Low
Report
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]
11/12
04:05 pm
lyel
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Medium
Report
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
11/11
07:08 pm
lyel
Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]
Low
Report
Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]
11/10
07:41 am
lyel
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]
11/10
07:30 am
lyel
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Low
Report
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
11/3
09:00 am
lyel
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Low
Report
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
10/3
03:40 pm
lyel
Lyell Immunopharma (NASDAQ:LYEL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lyell Immunopharma (NASDAQ:LYEL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.